Abstract

Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. RIPK3-mediated phosphorylation is thought to initiate MLKL oligomerization, membrane translocation and membrane disruption, although the precise choreography of events is incompletely understood. Here, we use single-cell imaging approaches to map the chronology of endogenous human MLKL activation during necroptosis. During the effector phase of necroptosis, we observe that phosphorylated MLKL assembles into higher order species on presumed cytoplasmic necrosomes. Subsequently, MLKL co-traffics with tight junction proteins to the cell periphery via Golgi-microtubule-actin-dependent mechanisms. MLKL and tight junction proteins then steadily co-accumulate at the plasma membrane as heterogeneous micron-sized hotspots. Our studies identify MLKL trafficking and plasma membrane accumulation as crucial necroptosis checkpoints. Furthermore, the accumulation of phosphorylated MLKL at intercellular junctions accelerates necroptosis between neighbouring cells, which may be relevant to inflammatory bowel disease and other necroptosis-mediated enteropathies.

Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. Here the authors show that MLKL trafficking and plasma membrane accumulation are crucial necroptosis checkpoints, and that accumulation of phosphorylated MLKL at intercellular junctions promotes necroptosis.

Details

Title
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis
Author
Samson, Andre L 1   VIAFID ORCID Logo  ; Zhang, Ying 1 ; Geoghegan, Niall D 1 ; Gavin, Xavier J 2 ; Davies, Katherine A 1   VIAFID ORCID Logo  ; Mlodzianoski, Michael J 1   VIAFID ORCID Logo  ; Whitehead, Lachlan W 1   VIAFID ORCID Logo  ; Frank, Daniel 1 ; Garnish, Sarah E 1 ; Fitzgibbon Cheree 2 ; Hempel, Anne 2 ; Young, Samuel N 2 ; Jacobsen, Annette V 1   VIAFID ORCID Logo  ; Cawthorne, Wayne 1 ; Petrie, Emma J 1 ; Faux, Maree C 1 ; Shield-Artin Kristy 1 ; Lalaoui Najoua 1   VIAFID ORCID Logo  ; Hildebrand, Joanne M 1   VIAFID ORCID Logo  ; Silke, John 1   VIAFID ORCID Logo  ; Rogers, Kelly L 1 ; Lessene Guillaume 3   VIAFID ORCID Logo  ; Hawkins, Edwin D 1   VIAFID ORCID Logo  ; Murphy, James M 1   VIAFID ORCID Logo 

 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); The University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); The University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Pharmacology and Therapeutics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2414911279
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.